Research on Optimal Immunization Strategy of Hepatitis B Vaccine in Chronic Kidney Disease Population
Condition: Hepatitis B Vaccine Interventions: Biological: 20 µg recombinant hepatitis B vaccine at months 0, 1, and 6; Biological: 20 µg recombinant hepatitis B vaccine at months 0, 1, 2,and 6; Biological: 60 µg recombinant hepatitis B vaccine at months 0, 1, 2,and 6 Sponsors: Shanxi Medical University; Centers for Disease Control and Prevention, China Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: China Health | Chronic Kidney Disease | Hepatitis | Hepatitis B | Hepatitis Vaccine | Research | Urology & Nephrology | Vaccines